Advertisement

Management of Side Effects of Therapy

  • Sanchia S. Goonewardene
  • Raj Persad
Chapter

Abstract

By 2030, prostate cancer is estimated to be the most common cancer overall [1]. Intermittent androgen deprivation is increasingly being employed as an alternative to continuous lifelong androgen deprivation therapy for men with advanced or recurrent prostate cancer [2].

References

  1. 1.
    Aarts MJ, Mols F, Thong MS, Louwman MW, Coebergh JW, van de Poll-Franse LV. Long-term prostate cancer survivors with low socioeconomic status reported worse mental health-related quality of life in a population-based study. Urology. 2010;76:1224–30.CrossRefGoogle Scholar
  2. 2.
    Akbal C, Tinay I, Simsek F, Turkeri LN. Erectile dysfunction following radiotherapy and brachytherapy for prostate cancer: pathophysiology, prevention and treatment. Int Urol Nephrol. 2008;40:355–63.CrossRefGoogle Scholar
  3. 3.
    Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017;71(4):618–29.CrossRefGoogle Scholar
  4. 4.
    Albersen M, Orabi H, Lue TF. Evaluation and treatment of erectile dysfunction in the aging male: a mini-review. Gerontology. 2012;58:3–14.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Sanchia S. Goonewardene
    • 1
  • Raj Persad
    • 2
  1. 1.The Royal Free Hospital and UCLLondonUnited Kingdom
  2. 2.North Bristol NHS TrustBristolUnited Kingdom

Personalised recommendations